<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - WPI</title>
<description>International Business News - WPI</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>Watson gets FDA approval for BPH drug</title>
  <description>Watson Pharmaceuticals Inc. said late Wednesday the Food and Drug Administration approved its drug Rapaflo for the treatment of urinary problems. The drug is approved as a treatment for BPH, or benign prostatic hyperplasia, which has symptoms including decreased urine flow and more frequent urination.</description>
    <link>http://www.ibtimes.com/articles/20081009/watson-gets-fda-approval-for-bph-drug.htm</link> 
  <pubDate>Thu, 09 Oct 2008 07:56:46 EDT</pubDate>
  </item>


  <item>
  <title>Watson reports new data for bladder drug</title>
  <description>Watson Pharmaceuticals Inc. on Wednesday presented updated information on the effectiveness of its experimental topical gel to treat overactive bladder syndrome.</description>
    <link>http://www.ibtimes.com/articles/20081008/watson-reports-new-data-for-bladder-drug.htm</link> 
  <pubDate>Wed, 08 Oct 2008 10:46:39 EDT</pubDate>
  </item>


  <item>
  <title>Watson says it received generic Oxytrol challenge</title>
  <description>Drugmaker Watson Pharmaceuticals Inc. said Wednesday the patent on its overactive bladder patch Oxytrol is being challenged. Watson said it has received a paragraph IV certification letter, which means a rival has asked the Food and Drug Administration to approve a generic version of the drug. In such challenges, filers state that the patents protecting a branded drug are invalid, unenforceable, or that a generic version won't infringe on those patents.</description>
    <link>http://www.ibtimes.com/articles/20081001/watson-says-it-received-generic-oxytrol-challenge.htm</link> 
  <pubDate>Wed, 01 Oct 2008 18:14:24 EDT</pubDate>
  </item>


  <item>
  <title>Watson Pharma: Prostate drug is effective, safe</title>
  <description>Watson Pharmaceuticals Inc. on Monday reported results from four late stage trials of its drug candidate silodosin, saying the drug was well tolerated and reduced symptoms of prostate enlargement.</description>
    <link>http://www.ibtimes.com/articles/20080929/watson-pharma-prostate-drug-is-effective-safe.htm</link> 
  <pubDate>Mon, 29 Sep 2008 11:22:15 EDT</pubDate>
  </item>


  <item>
  <title>Ahead of the Bell: Generic drug makers</title>
  <description>A Wachovia analyst upgraded the generic drug sector on Monday, and raised his ratings on Teva Pharmaceutical Industries Ltd. and Watson Pharmaceuticals Inc. because they are trading at discounts to their peers.</description>
    <link>http://www.ibtimes.com/articles/20080922/ahead-of-the-bell-generic-drug-makers.htm</link> 
  <pubDate>Mon, 22 Sep 2008 09:18:29 EDT</pubDate>
  </item>


  <item>
  <title>Premarket roundup: Utilities, WABCO Holdings</title>
  <description>Among the premarket activity stories for Tuesday, Sept. 16, from AP Financial News: NEW YORK (AP)--Regulated utilities remain an attractive investment in a low-interest rate environment given expected net income growth of up to 9 percent, a Goldman Sachs analyst said Tuesday.</description>
    <link>http://www.ibtimes.com/articles/20080916/premarket-roundup-utilities-wabco-holdings.htm</link> 
  <pubDate>Tue, 16 Sep 2008 10:18:58 EDT</pubDate>
  </item>


  <item>
  <title>Ahead of the Bell: Generic Drug Developers</title>
  <description>Shares of generic drug developer Watson Pharmaceuticals Inc. could be ready for a downturn, while rivals Teva Pharmaceutical Industries Ltd. and Mylan Inc. are in more stable positions, according to Goldman Sachs.</description>
    <link>http://www.ibtimes.com/articles/20080916/ahead-of-the-bell-generic-drug-developers.htm</link> 
  <pubDate>Tue, 16 Sep 2008 08:11:22 EDT</pubDate>
  </item>


  <item>
  <title>$21M settlement ironed out for drug cost lawsuit</title>
  <description>Patients treated by a long list of mostly doctor-administered drugs over the past 17 years may be in line for a refund, thanks to the settlement of a class-action lawsuit that alleged price inflation.</description>
    <link>http://www.ibtimes.com/articles/20080911/21m-settlement-ironed-out-for-drug-cost-lawsuit.htm</link> 
  <pubDate>Thu, 11 Sep 2008 14:51:28 EDT</pubDate>
  </item>


  <item>
  <title>Watson spent $230,000 on lobbying in 2Q</title>
  <description>_ Drug developer Watson Pharmaceuticals Inc. spent $230,000 in the second quarter to lobby on generic drug issues, federal reimbursement on prescription drugs and proposals on a system for generic biotech drugs, according to a recent disclosure report.</description>
    <link>http://www.ibtimes.com/articles/20080826/watson-spent-230-000-on-lobbying-in-2q.htm</link> 
  <pubDate>Tue, 26 Aug 2008 16:38:35 EDT</pubDate>
  </item>


  <item>
  <title>Dried sweet potato and bamboo fungus recalled</title>
  <description>The following recalls have been announced:--Hop Lee Trading Co. Inc. is recalling 12-ounce plastic packages of Chinese-made Flower brand dried sweet potato because they contain sulfites that are not listed on the label. This could be a problem for people with sulfite sensitivity, such as some asthmatics. No incidents have been reported. The sweet potato was distributed to stores around the country in July and August. Details: by phone at 718-821-2315.</description>
    <link>http://www.ibtimes.com/articles/20080813/dried-sweet-potato-and-bamboo-fungus-recalled.htm</link> 
  <pubDate>Wed, 13 Aug 2008 09:38:40 EDT</pubDate>
  </item>


  <item>
  <title>Recalls</title>
  <description>The following recalls have been announced:--Hop Lee Trading Co. Inc. is recalling 12-ounce plastic packages of Chinese-made Flower brand dried sweet potato because they contain sulfites that are not listed on the label. This could be a problem for people with sulfite sensitivity, such as some asthmatics. No incidents have been reported. The sweet potato was distributed to stores around the country in July and August. Details: by phone at 718-821-2315.</description>
    <link>http://www.ibtimes.com/articles/20080812/recalls.htm</link> 
  <pubDate>Tue, 12 Aug 2008 19:53:17 EDT</pubDate>
  </item>


  <item>
  <title>Earnings roundup: Hospira, Polo Ralph Lauren</title>
  <description>Among the earnings stories for Wednesday, Aug. 6, from AP Financial News: LAKE FOREST, Ill. (AP)--Hospira Inc., which makes drug delivery systems and devices, said Wednesday its second-quarter profit more than doubled on higher sales and a dip in expenses, but the results still fell short of Wall Street forecasts.</description>
    <link>http://www.ibtimes.com/articles/20080806/earnings-roundup-hospira-polo-ralph-lauren.htm</link> 
  <pubDate>Wed, 06 Aug 2008 10:36:39 EDT</pubDate>
  </item>


  <item>
  <title>Outlook roundup: Polo Ralph Lauren,Protective Life</title>
  <description>Among the earnings projection stories for Wednesday, Aug. 6, from AP Financial News: NEW YORK (AP)--Apparel maker Polo Ralph Lauren Corp. on Wednesday raised its fiscal-year outlook above analyst expectations, following a strong fiscal first-quarter earnings report.</description>
    <link>http://www.ibtimes.com/articles/20080806/outlook-roundup-polo-ralph-lauren-protective-life.htm</link> 
  <pubDate>Wed, 06 Aug 2008 10:21:53 EDT</pubDate>
  </item>


  <item>
  <title>Watson Pharmaceuticals backs 2008 profit guidance</title>
  <description>Branded and generic drug maker Watson Pharmaceuticals Inc. on Wednesday backed its previous fiscal-year guidance, after posting a second-quarter profit in line with Wall Street predictions.</description>
    <link>http://www.ibtimes.com/articles/20080806/watson-pharmaceuticals-backs-2008-profit-guidance.htm</link> 
  <pubDate>Wed, 06 Aug 2008 09:03:07 EDT</pubDate>
  </item>


  <item>
  <title>Watson Pharmaceuticals 2Q profit rises</title>
  <description>Branded and generic drug maker Watson Pharmaceuticals Inc. said Wednesday its second-quarter profit jumped 66 percent on a gain related to a legal settlement and revenue increases at both its generic and branded divisions.</description>
    <link>http://www.ibtimes.com/articles/20080806/watson-pharmaceuticals-2q-profit-rises.htm</link> 
  <pubDate>Wed, 06 Aug 2008 08:48:55 EDT</pubDate>
  </item>


  <item>
  <title>Sector Snap: Wachovia cuts generic drugmakers</title>
  <description>Investment bank Wachovia downgraded four of the largest generic drug companies Monday, indicating it expects them to perform about as well as the overall market.</description>
    <link>http://www.ibtimes.com/articles/20080721/sector-snap-wachovia-cuts-generic-drugmakers.htm</link> 
  <pubDate>Mon, 21 Jul 2008 15:16:51 EDT</pubDate>
  </item>


  <item>
  <title>Sector Snap: Teva-Barr talk lifts generics makers</title>
  <description>Shares of Barr Pharmaceuticals Inc. soared Thursday on reports of buyout talks between Barr and industry leader Teva Pharmaceutical Industries Ltd. The speculation also lifted shares of other generic drug makers.</description>
    <link>http://www.ibtimes.com/articles/20080717/sector-snap-teva-barr-talk-lifts-generics-makers.htm</link> 
  <pubDate>Thu, 17 Jul 2008 15:17:07 EDT</pubDate>
  </item>


  <item>
  <title>Watson Pharma launches generic nausea drug</title>
  <description>Branded and generic drug maker Watson Pharmaceutical Inc. said Monday it launched a generic version of Solvay SA&amp;#39;s Marinol, which treats chemotherapy-induced nausea.</description>
    <link>http://www.ibtimes.com/articles/20080630/watson-pharma-launches-generic-nausea-drug.htm</link> 
  <pubDate>Mon, 30 Jun 2008 12:02:09 EDT</pubDate>
  </item>


  <item>
  <title>Barr shares rise on Bayer birth control pills deal</title>
  <description>Shares of Barr Pharmaceuticals Inc. rose Tuesday after the generic drug company announced an agreement to sell two Bayer birth control pills years before the last patents expire on the products.</description>
    <link>http://www.ibtimes.com/articles/20080624/barr-shares-rise-on-bayer-birth-control-pills-deal.htm</link> 
  <pubDate>Tue, 24 Jun 2008 12:24:56 EDT</pubDate>
  </item>


  <item>
  <title>Biovail stock falls after analyst cuts rating</title>
  <description>Shares of drug developer Biovail Corp. sank Friday after a CIBC analyst said generic drug launches will likely keep pressuring the company&amp;#39;s revenue and restructuring efforts will be costly.</description>
    <link>http://www.ibtimes.com/articles/20080620/biovail-stock-falls-after-analyst-cuts-rating.htm</link> 
  <pubDate>Fri, 20 Jun 2008 15:08:13 EDT</pubDate>
  </item>


</channel>
</rss>